| Literature DB >> 24288571 |
Qing Liu1, Jiqiang Li, Jing Wang, Jianping Li, Joseph S Janicki, Daping Fan.
Abstract
Myocardial ischemia-reperfusion (MIR) injury is a major contributor to the morbidity and mortality associated with coronary artery disease, which accounts for approximately 450,000 deaths a year in the United States alone. Chinese herbal medicine, especially combined herbal formulations, has been widely used in traditional Chinese medicine for the treatment of myocardial infarction for hundreds of years. While the efficacy of Chinese herbal medicine is well documented, the underlying molecular mechanisms remain elusive. In this review, we highlight recent studies which are focused on elucidating the cellular and molecular mechanisms using extracted compounds, single herbs, or herbal formulations in experimental settings. These studies represent recent efforts to bridge the gap between the enigma of ancient Chinese herbal medicine and the concepts of modern cell and molecular biology in the treatment of myocardial infarction.Entities:
Year: 2013 PMID: 24288571 PMCID: PMC3833114 DOI: 10.1155/2013/925625
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Effects and mechanisms of Chinese herbal medicine in myocardial ischemia-reperfusion (MIR) injury. During ischemia, oxygen is not available to accept the electrons in the metabolic degradation of substrates, and consequently anaerobic metabolites become important in the preservation of myocardial viability. However, free radicals and reactive oxygen species (ROS) formation is markedly increased in this procedure. Reperfusion also generates high ROS levels which have an adverse impact on specific signal transduction systems, thereby predisposing the heart to further oxidative cell damage. Damaged cell debris, fibrinogen, cytokines, and chemokines will activate the receptors, including TLRs, TNFR, and ILR, in the host inflammatory cells as well as the cardiomyocytes. This sterile inflammatory process leads to the formation of a vicious circle, whereby the cardiomyocyte TLRs, TNFR, and ILR are activated by inflammatory cell-generated ligands. Typically, this has an adverse impact on specific signal transduction systems (e.g., AMPK, JNK, and NF-κB pathways), thereby activating the caspase cascade. Elevated ROS levels also result in intracellular Ca2+ overload which adversely affects mitochondrial function by opening the mitochondrial permeability transition pore (MPTP). As a result, the balance between Bax and Bcl is interrupted and the caspase cascade is further activated, leading to apoptotic cell death and myocardial tissue damage. Injured tissue expresses SDF-1, which interacts with its specific receptors (e.g., CXCR4) to facilitate the trafficking, adhesion, and infiltration of bone marrow derived stem cells (BMSCs). BMSCs produce high levels of the endothelial cell-specific angiogenic factor, VEGF, which is a critical regulator of angiogenesis that includes the stimulation of proliferation, migration, and proteolytic activity of endothelial cells and eventually leads to an increase in vessel density and the facilitating of myocardial regeneration and remodeling. During the MIR injury process, there are seven target areas where Chinese herbal medicine can exert protective effects on cardiomyocyte. Examples are as follows: (1) anti-oxidation actions of Palmatine, Forsythoside B, and SiNi Decoction; (2) anti-inflammatory properties of Tanshinone IIA, Schisandrin B, and ShuMai Decoction; (3) anti-apoptosis ability of Salidroside, Tyrosol, and Cardiotonic Pill; (4) protection of mitochondrial function by Herba Cistanches, Cistanche, and Guanxin II; (5) increasing BMSCs migration by Tanshinone IIA and Salvianolic acid B (6) promoting angiogenesis by Radix et Rhizoma Rhodiolae Kirilowii, ShuMai Decoction and TongXinLuo Superfine; and (7) inhibiting Ca2+ overload by Astragaloside IV, Lycium barbarum, and Acanthopanax senticosus injection.
Efficacy and mechanisms of Chinese herb-derived compounds in the treatment of MIR.
| Mechanism of action in TCM terminology | Plant | Compound | Mechanism | Biomarker/Targets | In vivo/In vitro | References |
|---|---|---|---|---|---|---|
| Tonifying |
| Tanshinone IIA | Anti-inflammation | MCP-1, TGF- | In vivo | [ |
| Antioxidant | VEGF, HIF-1 | Both | [ | |||
| Antiapoptosis | Bcl-2/Bax, caspase-3 | Both | [ | |||
| Promote angiogenesis | VEGF, HIF-1 | In vivo | [ | |||
| Promote BMSCs migration | SCF-1, CXCR-4 | In vivo | [ | |||
| Sodium tanshinone IIA sulfonate | Anti-apoptosis | LDH, JNK, p38 | In vivo | [ | ||
| Magnesium tanshinoate B | Anti-apoptosis | p-JNK, cytochrome c, caspase-3 | In vitro | [ | ||
| Salvianolic acid A | Activate calcium channels | I-CaL | In vivo | [ | ||
| Salvianolic acid B | Promote angiogenesis | VEGF | In vivo | [ | ||
| Salvianolic acids | Antioxidant | 15-F2t-IsoP, ET-1, CK-MB | In vivo | [ | ||
| Reduce ME | CK | In vitro | [ | |||
| Tanshinone combined with salvianolic acids | Inhibit of intracellular calcium, and anti-apoptosis, antioxidants | ICAM-1, Ca2+ | In vivo | [ | ||
| Tanshinone IIA combined with salvianolic acid B | Antioxidant | CAT, L-arginine, eNOS, AMPK, Akt | In vivo | [ | ||
| Danshensu | Antioxidant, reduce ME | SOD, MDA; CKMB, LDH | In vivo | [ | ||
| Salvia miltiorrhiza extract | Antioxidant, reduce ME | MDA, SOD, and GPx; LDH, CK, GOT | In vivo | [ | ||
| Aqueous extracts of | Reduce ME, promote angiogenesis | CK-MB and cTnT, 6-keto-PGF-1 | In vivo | [ | ||
|
| Antioxidant | COX-2; TXB2, 6-keto-PGF1- | In vivo | [ | ||
|
| Saponin of red ginseng | Inhibit Ca2+ overload, up-regulate KATP | Ca2+; KATP; cTnI; PI3K | Both | [ | |
| Total ginsenosides | Antioxidant, anti-apoptosis | Ca2+; eNOS, iNOS, GR; PI3K, Akt | In vivo | [ | ||
| Radix Ginseng extracts | Antioxidant, reduce ME | NO, eNOS; CK, LDH | In vivo | [ | ||
|
| Astragaloside IV | Up-regulate KATP channel subunits, facilitate KATP currents | KATP channel subunits Kir6.1, Kir6.2, SUR2A, SUR2B | In vivo | [ | |
|
| Salidroside, tyrosol | Anti-apoptosis | caspase-3, p-JNK, cytochrome c | In vitro | [ | |
|
| 17-Methoxyl-7-hydroxy-benzene-furanchalcone | Antioxidant, anti-inflammation, and anti-apoptosis | MDA; TNF- | Both | [ | |
|
| Schisandrin B | Anti-inflammation and | Hsp25, Hsp70 | In vivo | [ | |
| Antioxidant | cytochrome P-450 | In vivo | [ | |||
|
|
| Increase Na+-K+-ATPase and Ca2+-ATPase, anti-apoptosis | Na+-K+-ATPase, Ca2+-ATPase; Bax, Bcl-2 | In vivo | [ | |
|
| ||||||
| Moving |
| Tetramethylpyrazine | Antioxidant, inhibit neutrophil | HO-1; Migrated neutrophil | In vivo | [ |
| Aqueous extracts of Rhizoma Chuanxiong | Reduce ME, promote angiogenesis | CK-MB, cTnT; 6-keto-PGF-1 | In vivo | [ | ||
|
| Extracts of | Antioxidant, anti-inflammation | ROS, MDA, SOD; CRP, TNF- | Both | [ | |
|
| Extracts of | Antioxidant, anti-inflammation | MDA, SOD; CRP, TNF- | In vivo | [ | |
| Notoginsengnosides | Reduce ME | CK | In vitro | [ | ||
|
| Asperosaponin VI | Antioxidant, reduce ME, and protect mitochondrial function | SOD, GOT, GPx, MDA; CK-MB, LDH, cTnT; ICDH, MDH, | In vivo | [ | |
| Anti-apoptosis, reduce ME | Bcl2/Bax, caspase-3; LDH, CREB, PI3K | In vitro | [ | |||
|
| Flavonoid of Herba Pyrolae | Antioxidant, reduce ME | SOD, MDA; CK, LDH | In vivo | [ | |
|
| Forsythoside B | Antioxidant, anti-inflammation | MDA, MPO, SOD, GPx;Tn-T, TNF- | In vivo | [ | |
|
| Hydroalcoholic extract of | Antioxidant, reduce ME | SOD, CAT; LDH, CK-MB | In vivo | [ | |
|
| Desmodium gangeticum | Stimulate muscarinic receptors | Muscarinic receptor | In vivo | [ | |
|
| ||||||
| Inducing |
| 3,5-Dimethoxy-4-(3-(2-carbonyl-ethyldisulfanyl)-propionyl)-benzoic acid | Anti-apoptosis | Caspase-3, Bcl-2/Bax, Akt | In vitro | [ |
| 4-Guanidino-n-butyl syringate | Inhibit Ca2+ overload, antiapoptosis | Ca2+; Bcl-2, Bax, LDH | In vivo | [ | ||
|
|
| Inhibit calcium overload | Ca2+ | In vivo | [ | |
|
| Oleanolic Acid | Anti-apoptosis | AMPK, p38, FOXO3 | In vitro | [ | |
|
| Tetrandrine | Inhibit neutrophil, antioxidant | neutrophil adhesion, Mac-1; ROS | In vivo | [ | |
|
| ||||||
| Cooling |
| Botanical Flavonoids | Antioxidant | ROS, NO, SOD, CAT, GPx | Both | [ |
|
| Palmatine | Antioxidant, reduce ME | SOD, MDA, COX-2; LDH, CK | In vivo | [ | |
|
| Cyclovirobuxine D | Antioxidant, reduce ME | KATP channel opening; NO, ROS, SOD, MDA; CPK, LDH, FFA | In vivo | [ | |
|
| ||||||
| Tonifying |
| 2-Methoxycinnamaldehyde | Antioxidant, anti-inflammation | VCAM-1,TNF- | In vivo | [ |
|
| A semipurified fraction of Herba Cistanches | Protect mitochondrial function, antioxidant, and anti-apoptosis | ATP-generation, mitochondrial uncoupling; GSH; caspase-3 | Both | [ | |
|
| ||||||
| Regulating |
| Corydalis yanhusuo extract | Anti-apoptosis | Bax, Bcl-2 | In vivo | [ |
|
| Magnolol | Antioxidant; inhibit neutrophil | MPO, superoxide anion; migrated neutrophil | In vivo | [ | |
Efficacy and mechanism of patent drugs made up of Chinese herbs in the treatment of MIR.
| Mechanism of action in TCM terminology | Patent drug name | Main ingredient | Mechanism | Biomarker/Targets | In vivo/In vitro | References |
|---|---|---|---|---|---|---|
| Activating |
| Salvia, arrowroot, woody, hawthorn, panax | Antioxidant, promote angiogenesis | eNOS; VCAM-1 | In vivo | [ |
|
| Ginseng, leeches, scorpion, Eupolyphaga, centipede, et al | Antioxidant, proangiogenesis | NO, eNOS; vWF, Hhcy | In vivo | [ | |
|
| Peanut shells | Promote angiogenesis | vWF, VEGF | In vivo | [ | |
|
| ||||||
| Moving |
| Safflower, red peony, salvia, Chuanxiong, and so forth | Anti-apoptosis, protect mitochondrial function | Caspase-3, Caspase-9, Bcl-2/Bax, cytochrome c, Akt | In vivo | [ |
|
| Rhizoma Chuanxiong, Radix Paeoniae Rubra | Anti-inflammation | TNF- | In vivo | [ | |
|
| ||||||
| Replenishing |
| Radix Ginseng, Cornu Cervi, Cordyceps, Radix Salviae, Semen Allii, and so forth | Antioxidant, protect mitochondrial function | GSH, | In vivo | [ |
|
| Acanthopanax | Antioxidant, inhibit Ca2+ overload | SOD, MDA, GPx; Ca2+ | In vivo | [ | |
|
| Ginseng total saponins, total salvianolic, corydalis | Antioxdiant | SOD, MDA | In vivo | [ | |
|
| Ginseng, astragalus, Atractylodes, and so forth | Anti-inflammation | NF- | In vivo | [ | |
|
| ||||||
| Replenishing |
| Red ginseng, Monkshood | Antioxdiant, reduce ME, up-regulate-ATPase | SOD, GPx; LDH, CK; Na+-K+-ATP and Ca2+-ATP | In vivo | [ |
| Replenishing |
| Salvia, safflower | Antioxidant | SOD, MDA | In vivo | [ |
|
| Salvia miltiorrhiza | Anti-apoptosis | Caspase-3, Akt | In vivo | [ | |
Efficacy and mechanism of single Chinese herbs in the treatment of MIR.
| Mechanism of action in TCM terminology | Herb | Mechanism | Biomarker/Targets | In vivo/In vitro | References |
|---|---|---|---|---|---|
| Replenishing and moving |
| Promote angiogenesis | VEGFR (Flt-1, KDR, and Tie-2) | In vivo | [ |
|
| Antioxidant | TRP32, ROS, and Trx-1 | Both | [ | |
|
| Recovery of contractile dysfunction | Perfusion pressure, aortic flow, and coronary flow | In vivo | [ |
Efficacy and mechanisms of Chinese herb decoctions in the treatment of MIR.
| Mechanism of action in TCM terminology | Decoction | Constituent herbs | Mechanism | Biomarker/Targets | In vivo/In vitro | References |
|---|---|---|---|---|---|---|
| Tonifying |
| Astragali and Angelica roots | Antioxidant, protect mitochondrial function | GSH, GSSG, GRD | In vivo | [ |
|
| Astragalus, angelica, red peony, earthworm, and so forth | Reduce ME | LDH, CK, AST; CD40-CD40L | In vivo | [ | |
|
| ||||||
| Replenishing |
| Astragalus mongholicus, Salvia miltiorrhiza, Eupolyphaga, | Anti-inflammation | TNF- | In vivo | [ |
| Promote angiogenesis | VEGF, PDGF-BB, PI3K, Akt | In vivo | [ | |||
| Invigorating |
| Aconite, ginger, and licorice | Antimitochondrial oxidation | SOD, MDA, MnSOD mRNA | In vivo | [ |
|
| ||||||
| Moving |
| Salvia, Rhizoma Chuanxiong, and safflower | Anti-apoptosis | TUNEL | In vivo | [ |
| Enriching |
| Radix Salvia miltiorrhiza, and Radix Puerariae lobatae | Antioxidant | Redox-sensitive PKC | In vivo | [ |
|
| ||||||
| Enrich |
| Radix, Rhizoma Rhodiolae kirilowii | Promote angiogenesis | vWF, VEGF, HIF-1 | In vivo | [ |